CareDx vs Veracyte
CDNA and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CDNA and VCYT compare
CareDx is the larger company, worth 2.1 times as much as Veracyte ($4.3B against $2.0B).
On earnings, Veracyte is cheaper: it trades at 16.3× trailing earnings, against 34.0× for CareDx.
CareDx grew revenue faster over the last twelve months (38.9% versus 17.5% for Veracyte).
CareDx keeps more of each dollar of sales as profit, with a net margin of 25.9% compared with 21.8% at Veracyte.
Veracyte scores higher on the StockData Score (17 against 12 for CareDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CDNA | VCYT |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $2.0B |
| Share price | $81.17 | $25.11 |
| Change, 1 year | 386% | −40.7% |
| Change, 5 years | 88.7% | −49.1% |
| Beta (5Y) | 1.52 | 1.79 |
| Employees | 765 | 755 |
| StockData Score | ||
| Total score | 12 | 17 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 2 | 4 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 34.0× | 16.3× (better) |
| P/S | 8.6× | 3.5× (better) |
| P/B | 9.1× | 1.4× (better) |
| EV/EBITDA | 29.9× | 15.0× (better) |
| P/FCF | – | 12.5× |
| FCF yield | – | 8.0% |
| Fair value | $66.02 | $41.13 |
| Margin of safety | −22.9% | 38.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 38.9% (better) | 17.5% |
| Revenue growth, 5Y average | 14.6% | 34.5% (better) |
| Net income growth (TTM) | 82.6% | 318% (better) |
| EPS growth (TTM) | – | 305% |
| Profitability | ||
| Gross margin | – | 72.0% |
| Operating margin | 23.4% (better) | 17.1% |
| Net margin | 25.9% (better) | 21.8% |
| FCF margin | – | 27.8% |
| Return on equity | 33.0% (better) | 9.4% |
| Return on invested capital | 69.8% (better) | 9.1% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.31 | 5.56 (better) |
| Altman Z-score | 15.36 (better) | 9.26 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 111% |
| Held by insiders | 4.8% | 1.7% |
| Insider net buying, 12 months | −$18.1M (better) | −$18.6M |
| Short interest, % of float | 14.4% | 12.1% |
Go deeper
- CDNA stock overview
- CDNA income statement
- CDNA valuation and score
- VCYT stock overview
- VCYT income statement
- VCYT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.